Literature DB >> 15499570

Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.

Shari A Price-Schiavi1, Eran Andrechek, Nebila Idris, Peter Li, Min Rong, Jin Zhang, Coralie A Carothers Carraway, William J Muller, Kermit L Carraway.   

Abstract

Muc4 (also called Sialomucin complex) is a heterodimeric glycoprotein complex consisting of a peripheral O-glycosylated subunit ASGP-1 (ascites sialoglycoprotein-1) tightly but non-covalently bound to an N-glycosylated transmembrane subunit ASGP-2. Muc4/SMC can act as an intramembrane ligand for ErbB2 via an EGF-like domain present in the transmembrane subunit. The complex is developmentally regulated in normal rat mammary gland and overexpressed in a number of mammary tumors. Overexpression of Muc4/SMC has been shown to block cell-cell and cell-matrix interactions, protect tumor cells from immune surveillance, promote metastasis, and protect from apoptosis. We have investigated whether Muc4/SMC and ErbB2 are co-expressed and co-localized in normal rat mammary gland and whether Muc4/SMC-ErbB2 complex formation is developmentally regulated in this tissue. Muc4/SMC and ErbB2 have different expression patterns and regulatory mechanisms in the developing rat mammary gland, but both are maximally expressed during late pregnancy and lactation. The two proteins form a complex in lactating mammary gland which is not detected in the virgin gland. Moreover, this complex does not contain ErbB3. ErbB2 is co-localized with Muc4/SMC at the apical surfaces of ductal and alveolar cells in lactating gland; however, another form of ErbB2, recognized by a different antibody, localizes to the basolateral surfaces of these cells. ErbB2 phosphorylated on Tyr 1248 co-localized with Muc4/SMC at the apical surface but not at the basolateral surfaces of these cells. To investigate the function of Muc4 in the mammary gland, transgenic mice were derived using an MMTV-Muc4 construct. Interestingly, mammary gland development in the transgenic mice was aberrant, exhibiting a bifurcated pattern, including invasion down the blood vessel, similar to that exhibited by transgenic mice inappropriately expressing activated ErbB2 in the mammary gland. These data provide further evidence of the ability of Muc4/SMC to interact with ErbB2 and influence its behavior in normal epithelia. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15499570     DOI: 10.1002/jcp.20200

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  12 in total

Review 1.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

2.  Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2.

Authors:  Victoria P Ramsauer; Vanessa Pino; Amjad Farooq; Coralie A Carothers Carraway; Pedro J I Salas; Kermit L Carraway
Journal:  Mol Biol Cell       Date:  2006-04-19       Impact factor: 4.138

Review 3.  Structure, evolution, and biology of the MUC4 mucin.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Surinder K Batra
Journal:  FASEB J       Date:  2007-11-16       Impact factor: 5.191

Review 4.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

5.  Bile-salt-stimulated lipase and mucins from milk of 'secretor' mothers inhibit the binding of Norwalk virus capsids to their carbohydrate ligands.

Authors:  Nathalie Ruvoën-Clouet; Eric Mas; Séverine Marionneau; Patrice Guillon; Dominique Lombardo; Jacques Le Pendu
Journal:  Biochem J       Date:  2006-02-01       Impact factor: 3.857

6.  The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.

Authors:  Takuya Kitamura; Kevin Connolly; Lynnsie Ruffino; Tetsuo Ajiki; Aline Lueckgen; John DiGiovanni; Kaoru Kiguchi
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

7.  Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients.

Authors:  Noor Al-Dasooqi; Joanne M Bowen; Rachel J Gibson; Thomas Sullivan; Jude Lees; Dorothy M Keefe
Journal:  Invest New Drugs       Date:  2008-07-09       Impact factor: 3.850

8.  Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation.

Authors:  Federica Sotgia; Mathew C Casimiro; Gloria Bonuccelli; Manran Liu; Diana Whitaker-Menezes; Ozlem Er; Kristin M Daumer; Isabelle Mercier; Agnieszka K Witkiewicz; Carlo Minetti; Franco Capozza; Michael Gormley; Andrew A Quong; Hallgeir Rui; Philippe G Frank; Janet N Milliman; Erik S Knudsen; Jie Zhou; Chenguang Wang; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2009-02       Impact factor: 4.307

9.  MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer.

Authors:  Sukhwinder Kaur; Neil Sharma; Shiv Ram Krishn; Imay Lakshmanan; Satyanarayana Rachagani; Michael J Baine; Lynette M Smith; Subodh M Lele; Aaron R Sasson; Sushovan Guha; Kavita Mallya; Judy M Anderson; Michael A Hollingsworth; Surinder K Batra
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

10.  Transcript profiling of Elf5+/- mammary glands during pregnancy identifies novel targets of Elf5.

Authors:  Renee L Rogers; Isabelle Van Seuningen; Jodee Gould; Paul J Hertzog; Matthew J Naylor; Melanie A Pritchard
Journal:  PLoS One       Date:  2010-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.